These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. BMP type II receptor as a therapeutic target in pulmonary arterial hypertension. Orriols M; Gomez-Puerto MC; Ten Dijke P Cell Mol Life Sci; 2017 Aug; 74(16):2979-2995. PubMed ID: 28447104 [TBL] [Abstract][Full Text] [Related]
5. [New insights in the pathogenesis of pulmonary arterial hypertension]. Bordenave J; Tu L; Savale L; Huertas A; Humbert M; Guignabert C Rev Mal Respir; 2019 Apr; 36(4):433-437. PubMed ID: 31010759 [TBL] [Abstract][Full Text] [Related]
6. [The cancer paradigm in pulmonary arterial hypertension: towards anti-remodeling therapies targeting metabolic dysfunction?]. Dumas SJ; Humbert M; Cohen-Kaminsky S Biol Aujourdhui; 2016; 210(4):171-189. PubMed ID: 28327277 [TBL] [Abstract][Full Text] [Related]
7. Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension. Ruffenach G; Chabot S; Tanguay VF; Courboulin A; Boucherat O; Potus F; Meloche J; Pflieger A; Breuils-Bonnet S; Nadeau V; Paradis R; Tremblay E; Girerd B; Hautefort A; Montani D; Fadel E; Dorfmuller P; Humbert M; Perros F; Paulin R; Provencher S; Bonnet S Am J Respir Crit Care Med; 2016 Nov; 194(10):1273-1285. PubMed ID: 27149112 [TBL] [Abstract][Full Text] [Related]
8. Signal Mechanisms of Vascular Remodeling in the Development of Pulmonary Arterial Hypertension. Li MX; Jiang DQ; Wang Y; Chen QZ; Ma YJ; Yu SS; Wang Y J Cardiovasc Pharmacol; 2016 Feb; 67(2):182-90. PubMed ID: 26448276 [TBL] [Abstract][Full Text] [Related]
9. Molecular targets of the Warburg effect and inflammatory cytokines in the pathogenesis of pulmonary artery hypertension. Liu N; Parry S; Xiao Y; Zhou S; Liu Q Clin Chim Acta; 2017 Mar; 466():98-104. PubMed ID: 28093201 [TBL] [Abstract][Full Text] [Related]
10. An emerging strategy for targeted therapy of pulmonary arterial hypertension: Vasodilation plus vascular remodeling inhibition. Hu L; Zhao C; Chen Z; Hu G; Li X; Li Q Drug Discov Today; 2022 May; 27(5):1457-1463. PubMed ID: 35104622 [TBL] [Abstract][Full Text] [Related]
11. Current drug targets and future therapy of pulmonary arterial hypertension. Ito T; Ozawa K; Shimada K Curr Med Chem; 2007; 14(6):719-33. PubMed ID: 17346158 [TBL] [Abstract][Full Text] [Related]
12. Current therapeutics and practical management strategies for pulmonary arterial hypertension. Agarwal R; Gomberg-Maitland M Am Heart J; 2011 Aug; 162(2):201-13. PubMed ID: 21835279 [TBL] [Abstract][Full Text] [Related]
13. New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication. Guignabert C; Tu L; Girerd B; Ricard N; Huertas A; Montani D; Humbert M Chest; 2015 Feb; 147(2):529-537. PubMed ID: 25644906 [TBL] [Abstract][Full Text] [Related]
14. Cellular and molecular pathobiology of pulmonary arterial hypertension. Humbert M; Morrell NW; Archer SL; Stenmark KR; MacLean MR; Lang IM; Christman BW; Weir EK; Eickelberg O; Voelkel NF; Rabinovitch M J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):13S-24S. PubMed ID: 15194174 [TBL] [Abstract][Full Text] [Related]
15. Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension. Antigny F; Hautefort A; Meloche J; Belacel-Ouari M; Manoury B; Rucker-Martin C; Péchoux C; Potus F; Nadeau V; Tremblay E; Ruffenach G; Bourgeois A; Dorfmüller P; Breuils-Bonnet S; Fadel E; Ranchoux B; Jourdon P; Girerd B; Montani D; Provencher S; Bonnet S; Simonneau G; Humbert M; Perros F Circulation; 2016 Apr; 133(14):1371-85. PubMed ID: 26912814 [TBL] [Abstract][Full Text] [Related]
16. Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension. Dumas de la Roque E; Savineau JP; Bonnet S Pharmacol Ther; 2010 May; 126(2):186-99. PubMed ID: 20206649 [TBL] [Abstract][Full Text] [Related]
18. Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies. Waxman AB; Zamanian RT Am J Cardiol; 2013 Mar; 111(5 Suppl):1A-16A; quiz 17A-19A. PubMed ID: 23414683 [TBL] [Abstract][Full Text] [Related]
20. A review of therapeutic agents for the management of pulmonary arterial hypertension. Hahn SS; Makaryus M; Talwar A; Narasimhan M; Zaidi G Ther Adv Respir Dis; 2017 Jan; 11(1):46-63. PubMed ID: 27595643 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]